Letter: Estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 2, 2014, Pages 217-218

  Messori, A ^a   Maratea, D ^a   Fadda, V ^a   Trippoli, S ^a  

^a ESTAV Toscana Centro   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SOFOSBUVIR;

COMPARATIVE EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HUMAN; ITALY; LETTER; MORBIDITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84902797741     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12823     Document Type: Letter

References (10)

1. Koff RS,. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-874.
2. Hoofnagle JH, Sherker AH,. Therapy for hepatitis C-the costs of success. N Engl J Med 2014; 370: 1552-3.
3. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL,. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-65.
4. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J,. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8: iii-iv; 1-125.
5. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N,. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-205.
6. Hartwell D, Jones J, Baxter L, Shepherd J,. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011; 15: 1-210.
7. Cammà C, Petta S, Enea M, et al,. WEF Study Group. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 850-60.
8. Petta S, Cabibbo G, Enea M, et al,. WEF Study Group. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014; 59: 1692-705.
9. Messori A, Fadda V, Maratea D, Trippoli S,. Effect of discounting on estimation of benefits determined by hepatitis C treatment. World J Gastroenterol 2012; 18: 3032-4.
10. Mennini FS,. Costi e burden delle patologie HCV-correlate in Italia. Quotidiano Sanità, published 9 December 2013. Available at: http://www.quotidianosanita.it/allegati/create-pdf.php?all=1145451.pdf. Accessed May 12, 2014.